301060.SZ SHZ
Shanghai Labway Clinical Laboratory Co., Ltd.
1W: +0.7%
1M: +12.3%
3M: +37.1%
YTD: +5.0%
1Y: +12.2%
3Y: -26.9%
¥12.02 ($1.79)
+0.24 (+2.04%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$1.7B
+4.1% ▲
5Y CAGR: +8.6%
Gross Profit
$385M
+10.5% ▲
5Y CAGR: +2.0%
Operating Income
-$69M
+49.0% ▲
Net Income
-$109M
+22.7% ▲
EPS (Diluted)
$-0.27
+22.9% ▲
EBITDA
-$14M
+82.4% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.8B | $4.2B | $1.7B | $1.7B |
| YoY Growth | +7.3% | +43.6% | +136.1% | -60.1% | +4.1% |
| Cost of Revenue | $838M | $1.1B | $2.4B | $1.3B | $1.4B |
| Gross Profit | $400M | $680M | $1.8B | $348M | $385M |
| Gross Margin | 32.3% | 38.2% | 42.6% | 20.8% | 22.1% |
| R&D Expenses | $22M | $39M | $109M | $49M | $60M |
| SG&A Expenses | $20M | $189M | $275M | $100M | $87M |
| Operating Expenses | $213M | $349M | $645M | $484M | $454M |
| Operating Income | $178M | $319M | $949M | -$136M | -$69M |
| Operating Margin | 14.4% | 17.9% | 22.6% | -8.1% | -4.0% |
| Interest Expense | $401K | $4M | $11M | $8M | $11M |
| Income Before Tax | $162M | $318M | $904M | -$153M | -$103M |
| Tax Expense | $28M | $56M | $165M | $8M | -$4M |
| Net Income | $110M | $204M | $617M | -$142M | -$109M |
| Net Margin | 8.9% | 11.5% | 14.7% | -8.5% | -6.3% |
| EPS (Diluted) | $0.28 | $0.51 | $1.54 | $-0.35 | $-0.27 |
| EBITDA | $216M | $392M | $1.0B | -$80M | -$14M |
| Shares Outstanding | 401M | 401M | 401M | 405M | 405M |